Showing results (151-160 of 192) with videos related to
Sort By:
Pageof 20
Clinical Genitourinary Cancer|February 14, 2009
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trialEric Cheung, Jacek Pinski, Tanya Dorff, et al.Urologic Oncology|December 3, 2014
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute ForumColin P N Dinney, Donna Hansel, David McConkey, et al.Cancer Research|April 7, 2011
A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasisDezheng Dong, Christopher Stapleton, Biquan Luo, et al.Journal of Neuroinflammation|June 17, 2020
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosisWendy Gilmore, Brett T Lund, Peili Li, et al.Cancer Chemotherapy and Pharmacology|February 23, 2011
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium studyJane E Minturn, Audrey E Evans, Judith G Villablanca, et al.BMC Cancer|October 13, 2018
Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective studyLaurie L Brunette, Paulette Y Mhawech-Fauceglia, Lingyun Ji, et al.Urologic Oncology|February 10, 2021
Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray projectGang Wang, Peter C Black, Peter J Goebell, et al.Pharmacogenetics and Genomics|January 15, 2008
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancerGeorg Lurje, Wu Zhang, Dongyun Yang, et al.International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|June 11, 2015
Lymph Node Micrometastases in Early-Stage Cervical Cancer are Not Predictive of SurvivalMichael P Stany, Pamela J B Stone, Juan C Felix, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortiaAgustin A Garcia, Hal Hirte, Gini Fleming, et al.Pageof 20